April 24, 2012 | For Immediate Release

Names Operating Partners Charlie Mamrak as CEO and Fran Lunger as Chairman

Chicago, IL (April 24, 2012) – Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, today announced that it has completed the acquisition of SeraCare Life Sciences, Inc. (“SeraCare”), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics.

SeraCare, based in Milford, Massachusetts, serves the global life sciences industry by providing an innovative portfolio of diagnostic controls, plasma-derived reagents and molecular biomarkers used in the discovery, production, and clinical application of a variety of in vitro diagnostics. SeraCare also provides biobanking and contract research services to support clinical trials and research by government and academic institutions. SeraCare’s quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

With the closing of the transaction, Linden has added significant executive resources to SeraCare. Charlie Mamrak, an Operating Partner with Linden, has been named CEO. Previously, Mr. Mamrak was CEO of PML Microbiologicals and held management roles with both Fisher Scientific and Sigma-Aldrich. Additionally, Linden appointed Fran Lunger, also an Operating Partner with Linden and former CEO of Millipore Corporation, as board chairman. Lastly, Harold ‘Bud’ Ingalls has joined the company as CFO. Mr. Ingalls brings senior management experience including President of ArunA Biomedical and CFO of CardioMEMS and Serologicals Corporation.

“SeraCare represents the latest platform in Linden’s history of investing in life sciences, and we are excited by its opportunities to grow in serving some of the most important and dynamic firms in molecular diagnostics,” said Brian Miller, a Managing Partner at Linden. “Augmenting the existing team at SeraCare with our Operating Partners provides greater opportunities for SeraCare to succeed. The collaboration between operating depth and sector focus in transactions has enabled Linden to add significant value to our portfolio over time.”

“Linden’s life science expertise and understanding of the market will help us leverage SeraCare’s core capabilities to deliver even more value to our customers,” Mr. Mamrak said. “With a strong infectious disease and molecular biology foundation that is backed by an excellent team, SeraCare is positioned to be the global leader in human biologic and disease state reference material and to capitalize on the need for quality diagnostic data to support advances in precision medicine.”

William Blair & Company, LLC acted as Linden’s financial advisor, and Kirkland & Ellis LLP served as legal counsel to Linden. MidCap Financial, LLC led the senior credit facility and mezzanine financing was provided by BB&T Capital Partners.